<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7A0397DD-E0C6-4EA3-8031-B841D2503C4D"><gtr:id>7A0397DD-E0C6-4EA3-8031-B841D2503C4D</gtr:id><gtr:name>Royal Holloway, University of London</gtr:name><gtr:address><gtr:line1>Egham Hill</gtr:line1><gtr:line4>Egham</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>TW20 0EX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>School of Clinical Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7A0397DD-E0C6-4EA3-8031-B841D2503C4D"><gtr:id>7A0397DD-E0C6-4EA3-8031-B841D2503C4D</gtr:id><gtr:name>Royal Holloway, University of London</gtr:name><gtr:address><gtr:line1>Egham Hill</gtr:line1><gtr:line4>Egham</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>TW20 0EX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/867912CB-14FB-4DC7-85D7-C960853AAC96"><gtr:id>867912CB-14FB-4DC7-85D7-C960853AAC96</gtr:id><gtr:firstName>Angeleen</gtr:firstName><gtr:surname>Fleming</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0901339"><gtr:id>8CE81FFB-0855-49F2-B67E-A17AC40247C2</gtr:id><gtr:title>Strategic Skills Award</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901339</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2011-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>231303</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Holloway, University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biological Sciences Royal Holloway</gtr:department><gtr:description>The effect of aggresomes on centrosome function</gtr:description><gtr:id>968A2363-62CA-460F-90C9-0784BDAE7E88</gtr:id><gtr:impact>Awarded Parkinson's UK Innovation grant (notified of award in November 2012 - grant not active yet).</gtr:impact><gtr:partnerContribution>Lead applicant on successful grant application to Parkinson's UK. This group will perform the majority of the work proposed in the grant application.</gtr:partnerContribution><gtr:piContribution>Intellectual input into project design, co-applicant on successful grant application to Parkinson's UK. Construction of zebrafish cDNA constructs.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biochemical Society Summer Studentship</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Biochemical Society</gtr:fundingOrg><gtr:fundingRef>Biochemical Society Grant: Fleming</gtr:fundingRef><gtr:id>2528D90B-1955-4E1E-87BF-46FE033B221F</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's UK Innovation Grant (co-applicant)</gtr:description><gtr:fundingOrg>Parkinson's UK (Parkinson's Disease Society)</gtr:fundingOrg><gtr:id>92D54BEC-CB89-4620-AD3C-BB2D4681AD73</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Zebrafish transgenic line expressing human MAPT (tau) under the control of the zebrafish rhodopsin promoter. Expression is restricted to the rod photoreceptors therefore the line is viable and has considerable 3Rs benefits over models with pan-neuronal expression. The model is suitable for studying mechanisms of Alzheimer's disease, tau distribution and clearance, genetic and small molecule disease modifiers.</gtr:description><gtr:id>BA635396-DB2A-4D85-8050-A614C79486F0</gtr:id><gtr:impact>Used to assess genes identified in human GWAS studies for their impact on disease progression in this model - paper in preparation for submission in Dec 2012</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Zebrafish transgenic line expressing human tau</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5C44D1EC-7BFA-463D-B3EF-80341F3C70EC"><gtr:id>5C44D1EC-7BFA-463D-B3EF-80341F3C70EC</gtr:id><gtr:title>Complex inhibitory effects of nitric oxide on autophagy.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/caf3d032b5e39560b0be5e4330259686"><gtr:id>caf3d032b5e39560b0be5e4330259686</gtr:id><gtr:otherNames>Sarkar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4BBAC96E-DFAA-4EF7-96C2-760712E46F59"><gtr:id>4BBAC96E-DFAA-4EF7-96C2-760712E46F59</gtr:id><gtr:title>Zebrafish as a model to understand autophagy and its role in neurological disease.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aa5fd646b6c75048c7799638b384e965"><gtr:id>aa5fd646b6c75048c7799638b384e965</gtr:id><gtr:otherNames>Fleming A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7D3441CD-D55B-4D0B-B2AD-69A754886DD4"><gtr:id>7D3441CD-D55B-4D0B-B2AD-69A754886DD4</gtr:id><gtr:title>Zebrafish in pharmaceutical industry research: finding the best fit</gtr:title><gtr:parentPublicationTitle>Drug Discovery Today: Disease Models</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aa5fd646b6c75048c7799638b384e965"><gtr:id>aa5fd646b6c75048c7799638b384e965</gtr:id><gtr:otherNames>Fleming A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/247C7F01-B2F3-44DD-8B34-6AC5A1253C73"><gtr:id>247C7F01-B2F3-44DD-8B34-6AC5A1253C73</gtr:id><gtr:title>The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0e4d0d17bff35bbe032cf13e6a9e6a68"><gtr:id>0e4d0d17bff35bbe032cf13e6a9e6a68</gtr:id><gtr:otherNames>Lichtenberg M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1C4C744-EFCF-498C-9647-04A309C8B210"><gtr:id>E1C4C744-EFCF-498C-9647-04A309C8B210</gtr:id><gtr:title>Chemical modulators of autophagy as biological probes and potential therapeutics.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aa5fd646b6c75048c7799638b384e965"><gtr:id>aa5fd646b6c75048c7799638b384e965</gtr:id><gtr:otherNames>Fleming A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18ABB14A-D778-4142-9DDB-BE97D4354919"><gtr:id>18ABB14A-D778-4142-9DDB-BE97D4354919</gtr:id><gtr:title>Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b957f5c686493ef530aa6c8d8777989"><gtr:id>1b957f5c686493ef530aa6c8d8777989</gtr:id><gtr:otherNames>Underwood BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901339</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>